Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Mikhael

Showing results (61-70 of 104) with videos related to

Pageof 11
Sort By:
Hematological Oncology|February 25, 2024
Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA studyThierry Facon, Philippe Moreau, Ivan Špicka, et al.
American Journal of Hematology|September 2, 2016
Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myelomaTania Jain, Amylou C Dueck, Heidi E Kosiorek, et al.
Leukemia & Lymphoma|July 12, 2014
Impact of race and ethnicity on outcomes and health care utilization after allogeneic hematopoietic cell transplantationNandita Khera, Yu-Hui Chang, James Slack, et al.
Transplantation and Cellular Therapy|November 13, 2022
Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior TransplantationThomas G Martin, Marcelo Capra, Mohamad Mohty, et al.
Clinical Hematology International|October 1, 2021
Plasma Cell Leukemia - Facts and Controversies: More Questions than Answers?Anna Suska, David H Vesole, Jorge J Castillo, et al.
American Journal of Hematology|August 6, 2019
Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE scoreKristen M Sanfilippo, Suhong Luo, Tzu-Fei Wang, et al.
Hemasphere|July 17, 2025
Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myelomaOla Landgren, Noa Biran, Elizabeth K O'Donnell, et al.
Blood Advances|May 20, 2022
Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myelomaThomas Martin, Joseph Mikhael, Roman Hajek, et al.
Blood Cancer Journal|February 19, 2021
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of lifeEvangelos Terpos, Joseph Mikhael, Roman Hajek, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 14, 2018
Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective StudyTania Jain, Heidi E Kosiorek, Shu T Kung, et al.
Pageof 11

Showing results (61-70 of 104) with videos related to

Sort By:
Pageof 11
Hematological Oncology|February 25, 2024
Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA studyThierry Facon, Philippe Moreau, Ivan Špicka, et al.
American Journal of Hematology|September 2, 2016
Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myelomaTania Jain, Amylou C Dueck, Heidi E Kosiorek, et al.
Leukemia & Lymphoma|July 12, 2014
Impact of race and ethnicity on outcomes and health care utilization after allogeneic hematopoietic cell transplantationNandita Khera, Yu-Hui Chang, James Slack, et al.
Transplantation and Cellular Therapy|November 13, 2022
Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior TransplantationThomas G Martin, Marcelo Capra, Mohamad Mohty, et al.
Clinical Hematology International|October 1, 2021
Plasma Cell Leukemia - Facts and Controversies: More Questions than Answers?Anna Suska, David H Vesole, Jorge J Castillo, et al.
American Journal of Hematology|August 6, 2019
Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE scoreKristen M Sanfilippo, Suhong Luo, Tzu-Fei Wang, et al.
Hemasphere|July 17, 2025
Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myelomaOla Landgren, Noa Biran, Elizabeth K O'Donnell, et al.
Blood Advances|May 20, 2022
Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myelomaThomas Martin, Joseph Mikhael, Roman Hajek, et al.
Blood Cancer Journal|February 19, 2021
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of lifeEvangelos Terpos, Joseph Mikhael, Roman Hajek, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 14, 2018
Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective StudyTania Jain, Heidi E Kosiorek, Shu T Kung, et al.
Pageof 11